CTLA4 and cancer: Hence, Cancer cells establish immune privilege by upregulating the expression of inhibitory ligands, such as PD-L1, CTLA-4, LAG-3, TIM-3, and GAL9, which engage their cognate receptors on T cells, effectively transmitting a “stop” signal that abrogates T cell activation and function (56).